论文部分内容阅读
吉兰—巴雷综合征(GBS)是一种以快速进行性四肢麻木无力为特点的多神经根神经病,静脉注射免疫球蛋白(IVIG)及血浆置换(PE)成为国内外指南推荐的主要治疗方式.但是由于该病发病机制尚不明确,疾病谱不断增加,采用标准化治疗患者的恢复情况和临床结局差别很大.因此,如何尽早识别并干预预后不佳的患者具有重要意义.文章通过回顾近年来国内外关于GBS预后评价的研究,旨在介绍GBS相关的预后因素,以期指导临床工作,并展望未来可能的研究方向.“,”Guillain-Barré syndrome (GBS) is a polyradiculoneuropathy characterized by a rapidly progressive bilateral paresis of the limbs. The intravenous immunoglobulins (IVIG) and plasma exchanges ( PE) have long been proven effective and become the primary treatment recommended by the current guidelines at home and abroad. However, because the patho-genesis of the disease is not clear and the spectrum of disease is increasing, the recovery and clinical outcomes of patients trea-ted with standardized treatment are quite different. Therefore, it is important to identify and interfere with patients with poor prognosis as early as possible. This article reviews the research on the prognostic evaluation of GBS at home and abroad in re-cent years, and aims to introduce GBS related prognostic factors in order to guide the clinical work and to look forward to the possible future research direction.